Vera Therapeutics Inc Cl A (VERA) Stock Price, Quote & News

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 770 0077

Website: veratx.com

Address:

2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

flamingojack May. 13 at 10:25 PM

$VERA may be the last chance for under $40

0 · Reply

Irish_lass May. 13 at 7:38 PM

$VERA

0 · Reply

BullJack May. 13 at 7:36 PM

$LONA perceptive advisors took a 20% stake and was granted a board seat. Premier biotech fund. $VERA i like a continued run up to FDA DATE $FBIO and DERM - following buymoremakemore’s DD here. The rosacea treatment seems to really be working. Tons of Reddit posts by public. Sales should only increase.

1 · Reply

BioSpecialOne May. 12 at 2:03 PM

$VERA I like this one

0 · Reply

Quantumup May. 12 at 12:13 PM

H.C. Wainwright⬆️ $CLYM's PT to $20/said: We draw investors' attention to the fact that Climb Bio is poised to have a catalyst-rich year, with multiple clinical milestones slated for achievement with both lead assets from its portfolio. $RHHBY $VERA BIIB VRTX H.C. Wainwright added—Enrollment is ongoing in the PrisMN Phase 2 primary membranous nephropathy (pMN) trial of Climb Bio's most advanced asset, budoprutug. PrisMN is a global open-label, dose-ranging Phase 2 study designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 development. Initial data from this trial is anticipated in 4Q26. We reiterate our Buy rating, while raising our 12-month price target to $20 from the prior $15 per share.

0 · Reply

Irish_lass May. 11 at 2:38 PM

$VERA Opportunity to add last week was a gift.

2 · Reply

Night_Owl_Biotech May. 11 at 3:26 AM

$VERA valuation & revenue multiples v 17 peer commercial-stage bios acquired just before/after FDA approval. The average peer 5-year revenue multiple was 1.35X &/or a 0.37X 10-year multiple. If VERA analyst consensus revenue estimates are credible AND if VERA were worth ab average 5 & 10-year multiples consistent with the 17 peers (2 HUGE IFs) that would come to $4.2-$4.4B in enterprise value. Adding VERA's $500MM net cash/debt would be $4.7-$4.9B in market cap. Using VERA's 3/31/26 cap table, that would come to $59-$62 per fully diluted share. This is a simple "what-if" as we're trying to learn more. Just to be clear, we have no idea what VERA might be worth in an acquisition. We also are unaware if VERA's gross margin profile will be consistent with these peers. This is not investment advice. Can any VERA investor comment on Atacicept's projected gross margin profile (as a subq injection) &/or speculate on whether or not VERA could fetch a premium M&A revenue multiple? $XBI $IBB

2 · Reply

flamingojack May. 9 at 6:31 PM

$VERA Does anyone else think the FDA will announce their decision early since atacicept meets an unmet need?

1 · Reply

Merlintrader May. 9 at 1:05 PM

$VERA 3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics https://www.merlintrader.com/biotech-fda-catalysts-near-term/

0 · Reply

flamingojack May. 8 at 9:02 PM

$VERA about to kiss 37. That line up is looking pretty straight.

0 · Reply

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-07T20:08:52.000Z - 6 days ago

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

May 7, 2026, 7:30 AM EDT - 6 days ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 4, 2026, 7:30 AM EDT - 9 days ago

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Mar 25, 2026, 7:30 AM EDT - 7 weeks ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

2026-03-10T23:05:13.000Z - 2 months ago

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

VRTX

2026-03-10T12:03:07.000Z - 2 months ago

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

VRTX

2026-03-05T14:16:31.000Z - 2 months ago

Vera Therapeutics appoints Hite to Board of Directors

Mar 5, 2026, 9:00 AM EST - 2 months ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Mar 3, 2026, 11:10 AM EST - 2 months ago

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:11:41.000Z - 2 months ago

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

2026-02-26T12:46:30.000Z - 2 months ago

Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)

2026-02-26T12:46:00.000Z - 2 months ago

Vera Therapeutics sees cash runway through atacicept commercial launch

Feb 26, 2026, 7:30 AM EST - 2 months ago

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Feb 24, 2026, 8:00 AM EST - 2 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

2026-01-28T12:35:58.000Z - 3 months ago

Vera Therapeutics appoints Skelton as Chief Commercial Officer

Jan 28, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Jan 13, 2026, 5:15 PM EST - 4 months ago

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T12:37:21.000Z - 4 months ago

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Jan 7, 2026, 7:30 AM EST - 4 months ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Jan 6, 2026, 2:31 PM EST - 4 months ago

Wells Fargo sees short squeeze ahead: here are three stocks to play it

HRI MTDR

2025-12-21T23:50:11.000Z - 5 months ago

Short Report: Vera Therapeutics bears retreat as stock rallies

MBLY MDGL NGNE

2025-12-19T12:35:35.000Z - 5 months ago

Vera Therapeutics price target raised to $66 from $48 at BofA

2025-12-19T12:25:27.000Z - 5 months ago

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

2025-12-19T12:00:44.000Z - 5 months ago

Vera Therapeutics price target lowered to $96 from $99 at JPMorgan

2025-12-16T01:50:18.000Z - 5 months ago

Vera Therapeutics director buys $250K in common stock

2025-12-11T13:26:34.000Z - 5 months ago

Vera Therapeutics price target raised to $33 from $23 at Wedbush

2025-12-10T03:25:17.000Z - 5 months ago

Vera Therapeutics 6.14M share Secondary priced at $42.50

Dec 9, 2025, 8:57 PM EST - 5 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

2025-12-08T21:16:57.000Z - 5 months ago

Vera Therapeutics offers to sell up to $200M in common stock

Dec 8, 2025, 4:01 PM EST - 5 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

2025-12-08T13:35:15.000Z - 5 months ago

Vera Therapeutics price target raised to $97 from $75 at Evercore ISI

Dec 3, 2025, 4:00 PM EST - 5 months ago

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:45 AM EST - 5 months ago

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 4:05 PM EST - 6 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Nov 13, 2025, 1:30 PM EST - 6 months ago

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 7:29 AM EST - 6 months ago

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 7, 2025, 6:27 PM EST - 6 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 6, 2025, 4:30 PM EST - 6 months ago

Vera Therapeutics Transcript: KOL Event

Nov 6, 2025, 9:51 AM EST - 6 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 5, 2025, 7:29 AM EST - 6 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 17, 2025, 9:12 AM EDT - 7 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Sep 4, 2025, 9:10 AM EDT - 8 months ago

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 7:05 PM EDT - 10 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2025, 3:15 PM EDT - 1 year ago

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 4, 2025, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Mar 4, 2025, 9:10 AM EST - 1 year ago

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:25 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 9:30 AM EST - 1 year ago

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: R&D Day 2024

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Sep 18, 2024, 9:10 AM EDT - 1 year ago

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 11, 2024, 4:01 PM EDT - 2 years ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 25, 2024, 9:40 AM EDT - 2 years ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 9, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 20, 2024, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 2:10 PM EST - 2 years ago

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 2, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Jan 25, 2024, 6:30 AM EST - 2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 9, 2024, 6:00 PM EST - 2 years ago

Vera Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:01 AM EST - 2 years ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Dec 27, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 4, 2023, 10:00 AM EDT - 2 years ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

flamingojack May. 13 at 10:25 PM

$VERA may be the last chance for under $40

0 · Reply

Irish_lass May. 13 at 7:38 PM

$VERA

0 · Reply

BullJack May. 13 at 7:36 PM

1 · Reply

BioSpecialOne May. 12 at 2:03 PM

$VERA I like this one

0 · Reply

Quantumup May. 12 at 12:13 PM

0 · Reply

Irish_lass May. 11 at 2:38 PM

$VERA Opportunity to add last week was a gift.

2 · Reply

Night_Owl_Biotech May. 11 at 3:26 AM

2 · Reply

flamingojack May. 9 at 6:31 PM

$VERA Does anyone else think the FDA will announce their decision early since atacicept meets an unmet need?

1 · Reply

Merlintrader May. 9 at 1:05 PM

$VERA 3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics https://www.merlintrader.com/biotech-fda-catalysts-near-term/

0 · Reply

flamingojack May. 8 at 9:02 PM

$VERA about to kiss 37. That line up is looking pretty straight.

0 · Reply

MorganHoratio May. 8 at 1:51 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $SPRO - 889,979 $TEM - 1,551,102 $TNYA - 915,705 $PATH - 7,034,337 $VERA - 241,264 Google’s Q1 13F is a definitive bet on Agentic AI and Data-Driven Healthcare! The 7M+ share stake in $PATH (UiPath) is a massive signal—as 2026 marks the rise of AI Agents, Google is weaponizing UiPath to bridge the gap between Gemini’s logic and enterprise execution. Meanwhile, $TEM (Tempus AI) just validated Google's thesis with a stellar Q1 beat, posting 36% revenue growth. Do you think Google’s $PATH position is the key to countering Microsoft’s automation dominance? Which play has more "moonshot" potential for the rest of 2026: the automation of $PATH or the precision of $TEM?

2 · Reply

Nabepe May. 7 at 1:45 PM

$VERA doubled my position

0 · Reply

flamingojack May. 7 at 11:44 AM

$VERA looking good 👍 https://finance.yahoo.com/sectors/healthcare/articles/vera-therapeutics-provides-business-reports-113000533.html

0 · Reply

forprofit12 May. 6 at 5:55 PM

$VERA doubled my position.

0 · Reply

Theflash88 May. 5 at 7:50 PM

$VERA Buyout incoming.. me thinks.

0 · Reply

Quantumup May. 5 at 11:11 AM

Chardan🏁 $CLYM and said: We initiate coverage on Climb Bio with a Buy rating and a $22 price target. $RHHBY $VERA TVTX VRDN AMGN NVS AZN Here's what else Chardan had to say in its initiation report: https://x.com/Quantumup1/status/2051619926608085497?s=20

0 · Reply